Compare · LUNA vs SYNH
LUNA vs SYNH
Side-by-side comparison of Luna Innovations Incorporated (LUNA) and Syneos Health Inc. (SYNH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LUNA and SYNH operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- SYNH is the larger of the two at $9.19B, about 42.4x LUNA ($216.7M).
- SYNH has more recent analyst coverage (19 ratings vs 4 for LUNA).
- Company
- Luna Innovations Incorporated
- Syneos Health Inc.
- Price
- $0.88-57.07%
- $42.98+0.01%
- Market cap
- $216.7M
- $9.19B
- 1M return
- +0.00%
- -
- 1Y return
- +0.00%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2006
- 2014
- News (4w)
- 0
- 0
- Recent ratings
- 4
- 19
Luna Innovations Incorporated
Luna Innovations Incorporated develops, manufactures, and markets fiber optic test, measurement, and control products worldwide. It operates through two segments, Lightwave and Luna Labs. The Lightwave segment offers test and measurement products, which include optical vector analyzer, optical backscatter reflectometers, and the Phoenix family of tunable lasers; and Hyperion sensing solution that enable full-spectrum data acquisition and flexible peak detect algorithms of fiber-bragg grating (FBG), long period FBGs and fabry-perot sensors with low-latency access to data for closed loop feedback applications. This segment also provides polarization control products, including components, modules, and instruments to measure, manage, and control polarization and group delay in fiber optic networks; tunable lasers; Terametrix terahertz gauging and imaging products that provides precise single and multi-layer thickness, density, basis weight, and caliper thickness measurements; ODiSI sensing solution, which provides distributed strain and temperature measurements; and Hyperion sensing products that targets fiber optic sensing applications. The Luna Labs segment provides applied research for customers principally in the areas of sensing and materials, such as coatings, adhesives, composites, and bio-engineered materials. The company sells its products to telecommunications companies, defense agencies, government system integrators, researchers, original equipment manufacturers, distributors, testing labs, and strategic partners directly, as well as through manufacturer representative organizations, partner and distribution channels, technical sales engineers, value added resellers, and independent sales representatives. Luna Innovations Incorporated was incorporated in 1990 and is headquartered in Roanoke, Virginia.
Syneos Health Inc.
Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various services spanning Phases I to IV of clinical development, including full service global studies, as well as individual service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services comprising deployment solutions; communications solutions, such as public relations, advertising, and medical communications; and consulting services. Its customers include small, mid-sized, and large companies in the pharmaceutical, biotechnology, and medical device industries. Syneos Health, Inc. has a partnership with VBI Vaccines Inc. for the commercialization of 3-antigen prophylactic hepatitis B vaccine in the United States, Europe, and Canada, which is in pending regulatory approvals. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina
Latest LUNA
- Luna Innovations Incorporated - Notice of Pendency and Proposed Settlement of Stockholder Derivative Action
- Luna Innovations Reports Q3 2025 Results Including Continued Bookings Growth and Margin Expansion
- Luna Announces Strong Start to 2025 with Substantial Bookings Growth
- Luna Innovations Announces Baker Tilly as New Independent Auditor
- Luna Innovations Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Luna Announces Updates on Operating Metrics and Intent to Deregister Stock
- SEC Form SCHEDULE 13G filed by Luna Innovations Incorporated
- Luna Innovations Incorporated filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits
- Luna Innovations Stock to Be Suspended from Nasdaq Listing
- Director Spiegel Gary converted options into 10,672 shares, increasing direct ownership by 15% to 81,625 units (SEC Form 4)
Latest SYNH
- Mitsubishi Tanabe Pharma America Celebrates Eight-Year Anniversary in the U.S.
- Mitsubishi Tanabe Pharma America to Showcase Breadth of Neurodegenerative Research at 2024 American Academy of Neurology Annual Meeting
- Mitsubishi Tanabe Pharma America Receives U.S. Food and Drug Administration Orphan Drug Exclusivity for RADICAVA ORS® (edaravone)
- NorthStar Medical Technologies, LLC Announces Appointment of Barbara Bodem and David Keeling to Board of Managers
- SEC Form 15-12G filed by Syneos Health Inc.
- Syneos Health Tapped PRA Health Sciences' Colin Shannon as the CEO Succeeding Michelle Keefe
- SEC Form 8-K filed by Syneos Health Inc.
- Zulueta Alfonso G returned $150,199 worth of shares to the company (8,356 units at $17.97), closing all direct ownership in the company (SEC Form 4)
- Wilkes David S. returned $213,839 worth of shares to the company (9,836 units at $21.74), closing all direct ownership in the company (SEC Form 4)
- Monaghan Matthew E. returned $850,411 worth of shares to the company (24,640 units at $34.51), closing all direct ownership in the company (SEC Form 4)